These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 14513853)

  • 21. From directly observed therapy to accompagnateurs: enhancing AIDS treatment outcomes in Haiti and in Boston.
    Behforouz HL; Farmer PE; Mukherjee JS
    Clin Infect Dis; 2004 Jun; 38 Suppl 5():S429-36. PubMed ID: 15156434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting HIV care costs using CD4 counts from clinical trials.
    Hill A; Gebo K
    Am J Manag Care; 2007 Sep; 13(9):524-8. PubMed ID: 17803366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The economics of effective AIDS treatment in Thailand.
    Over M; Revenga A; Masaki E; Peerapatanapokin W; Gold J; Tangcharoensathien V; Thanprasertsuk S
    AIDS; 2007 Jul; 21 Suppl 4():S105-16. PubMed ID: 17620745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prioritising access to antiretroviral therapy in resource-poor settings.
    Lange JM; van der Waals FW
    J HIV Ther; 2002 Aug; 7(3):59-62. PubMed ID: 12442166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Antiretroviral treatment of HIV infections in poor countries].
    Eskesen AN
    Tidsskr Nor Laegeforen; 2003 Nov; 123(22):3255-7. PubMed ID: 14714026
    [No Abstract]   [Full Text] [Related]  

  • 26. Antiretroviral therapy to treat and prevent HIV/AIDS in resource-poor settings.
    Garnett GP; Bartley L; Grassly NC; Anderson RM
    Nat Med; 2002 Jul; 8(7):651-4. PubMed ID: 12091892
    [No Abstract]   [Full Text] [Related]  

  • 27. Antiretroviral therapy where resources are limited.
    Reynolds SJ; Bartlett JG; Quinn TC; Beyrer C; Bollinger RC
    N Engl J Med; 2003 May; 348(18):1806-9. PubMed ID: 12724489
    [No Abstract]   [Full Text] [Related]  

  • 28. Community-based approaches to HIV treatment in resource-poor settings.
    Farmer P; Léandre F; Mukherjee JS; Claude M; Nevil P; Smith-Fawzi MC; Koenig SP; Castro A; Becerra MC; Sachs J; Attaran A; Kim JY
    Lancet; 2001 Aug; 358(9279):404-9. PubMed ID: 11502340
    [No Abstract]   [Full Text] [Related]  

  • 29. Integrated HIV prevention and care strengthens primary health care: lessons from rural Haiti.
    Walton DA; Farmer PE; Lambert W; Léandre F; Koenig SP; Mukherjee JS
    J Public Health Policy; 2004; 25(2):137-58. PubMed ID: 15255381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of HIV-infections: success or crisis?].
    Pokrovskiĭ VV
    Ter Arkh; 2001; 73(11):52-4. PubMed ID: 11806206
    [No Abstract]   [Full Text] [Related]  

  • 31. Global AIDS conference finds the issue is cash.
    Cullinan K
    Bull World Health Organ; 2002; 80(9):761-2. PubMed ID: 12378299
    [No Abstract]   [Full Text] [Related]  

  • 32. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens.
    Renaud-Théry F; Nguimfack BD; Vitoria M; Lee E; Graaff P; Samb B; Perriëns J
    AIDS; 2007 Jul; 21 Suppl 4():S89-95. PubMed ID: 17620758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is the time for an AIDS-free new generation different in resource-limited and industrialized countries?
    Russo G; Lichtner M; Traditi F; Vullo V
    AIDS; 2009 Jan; 23(3):293-6. PubMed ID: 19114853
    [No Abstract]   [Full Text] [Related]  

  • 34. Sustaining Treatment Costs: Who will Pay? Proceedings of a meeting, 27-29 November 2006, Washington, DC, USA.
    AIDS; 2007 Jul; 21 Suppl 4():S1-130. PubMed ID: 17969224
    [No Abstract]   [Full Text] [Related]  

  • 35. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.
    Lima VD; Johnston K; Hogg RS; Levy AR; Harrigan PR; Anema A; Montaner JS
    J Infect Dis; 2008 Jul; 198(1):59-67. PubMed ID: 18498241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agenda.
    Kent DM; McGrath D; Ioannidis JP; Bennish ML
    Clin Infect Dis; 2003 Jul; 37(Suppl 1):S13-24. PubMed ID: 12822128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-1 therapeutic vaccines.
    Kinloch-de Loes S; Autran B
    J Infect; 2002 Apr; 44(3):152-9. PubMed ID: 12099741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiretroviral therapy in sub-Saharan Africa: adherence lessons from tuberculosis and leprosy.
    Reid SE; Reid CA; Vermund SH
    Int J STD AIDS; 2004 Nov; 15(11):713-6. PubMed ID: 15537453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Drugs for antiretroviral therapy. The costs of HAART].
    Jablonowski H
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():21. PubMed ID: 19024911
    [No Abstract]   [Full Text] [Related]  

  • 40. HAART in India.
    John BV; Thomas S
    Lancet; 2004 Feb; 363(9407):493. PubMed ID: 14962542
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.